Corphena (dexchlorpheniramine maleate) NDC 73684-300

NDC codes

FDA NDC Directory

Product NDC (as listed)73684-300Labeler and product segments. Claims need a package NDC.

Product NDC at billing width73684-0300Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
73684-300-08	73684030008	237 mL in 1 BOTTLE, PLASTIC (73684-300-08)Marketed from Dec 22, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Corphena
Generic name (nonproprietary): dexchlorpheniramine maleate
Active ingredients: Dexchlorpheniramine maleate — 2 mg/5mL
Dosage form: Solution
Route: Oral
Labeler: BluCrest Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202520
Marketing start: Oct 22, 2025
Listing expires: Dec 31, 2026
Identifiers: Product ID 73684-300_4694618d-6999-29b1-e063-6394a90ab004SPL ID 4694618d-6999-29b1-e063-6394a90ab004SPL set ID 4694616b-4ef4-28a4-e063-6394a90ac5f6RxCUI 2183907UNII B10YD955QWUPC 0373684300088

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N473684030008 followed by a unit qualifier and the quantity

Package 73684-0300-08. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 22, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202520

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202520
Product	Strength	Form · route	Labeler	Product NDC
Rycloradexchlorpheniramine maleate	Dexchlorpheniramine maleate 2 mg/5mL	LiquidOral	CARWIN PHARMACEUTICAL ASSOCIATES, LLC	15370-150